The Health Impact Fund: how might it work for novel anticoagulants in atrial fibrillation?

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Global Heart

• Publication date

  2014-06-01

• Fields of study

  Medicine, Business

• Identifiers
  DOI 10.1016/j.gheart.2014.01.005PMID 25667097
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Explaining the decline in coronary heart disease mortality in the Czech Republic between 1985 and 2007

  2014cited by this paper
• Empowerment, patient centred care and self‐management

  2014cited by this paper
• Cost Effectiveness of Treatments for Stroke Prevention in Atrial Fibrillation: Focus on the Novel Oral Anticoagulants

  2013cited by this paper
• Efficacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: systematic review and network meta-analysis

  2013cited by this paper
• Atrial fibrillation: profile and burden of an evolving epidemic in the 21st century.

  2013cited by this paper
• Prasugrel vs clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a model-based cost-effectiveness analysis for Germany, Sweden, the Netherlands, and Turkey

  2013cited by this paper
• Access to patient-level data from GlaxoSmithKline clinical trials.

  2013cited by this paper
• A review of apixaban for stroke prevention in atrial fibrillation: insights from ARISTOTLE

  2013cited by this paper
• Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060.

  2013cited by this paper
• Are clinical trial data shared sufficiently today? No

  2013cited by this paper
• Big Pharma and social responsibility--the Access to Medicine Index.

  2013cited by this paper
• The new oral anti-coagulants and the phase 3 clinical trials - a systematic review of the literature

  2013cited by this paper
• The new patent regime and disease priorities in India

  2013cited by this paper
• Risk Profiles and Antithrombotic Treatment of Patients Newly Diagnosed with Atrial Fibrillation at Risk of Stroke: Perspectives from the International, Observational, Prospective GARFIELD Registry

  2013cited by this paper
• The Gap between Trial Data and Clinical Practice - An Analysis of Case Reports on Bleeding Complications Occurring under Dabigatran and Rivaroxaban Anticoagulation

  2013cited by this paper
• Ticagrelor or prasugrel for pre-hospital protocols in STEMI?

  2013cited by this paper
• An international longitudinal registry of patients with atrial fibrillation at risk of stroke (GARFIELD): the UK protocol

  2013cited by this paper
• What is the value of ‘me-too’ drugs?

  2013cited by this paper
• Age-specific and sex-specific mortality in 187 countries, 1970-2010: a systematic analysis for the Global Burden of Disease Study 2010.

  2012cited by this paper
• Novel Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation: Focus on Apixaban

  2012cited by this paper
• The global burden of atrial fibrillation and stroke: a systematic review of the epidemiology of atrial fibrillation in regions outside North America and Europe.

  2012cited by this paper
• Subclinical atrial fibrillation and the risk of stroke.

  2012cited by this paper
• Technologies for global health.

  2012cited by this paper
• Challenges to India's Pharmaceutical Patent Laws

  2012cited by this paper
• Switching from originator brand medicines to generic equivalents in selected developing countries: how much could be saved?

  2012cited by this paper
• Representativeness of the dabigatran, apixaban and rivaroxaban clinical trial populations to real-world atrial fibrillation patients in the United Kingdom: a cross-sectional analysis using the General Practice Research Database

  2012cited by this paper
• Use of evidence to support healthy public policy: a policy effectiveness-feasibility loop.

  2012cited by this paper
• An international model to predict recurrent cardiovascular disease.

  2012cited by this paper
• Systematic review of general burden of disease studies using disability-adjusted life years

  2012cited by this paper
• Population-Attributable Risks for Ischemic Stroke in a Community in South Brazil: A Case-Control Study

  2012cited by this paper
• Cost effectiveness of strategies to combat cardiovascular disease, diabetes, and tobacco use in sub-Saharan Africa and South East Asia: mathematical modelling study

  2012cited by this paper
• Apixaban versus Warfarin in Patients with Atrial Fibrillation

  2012cited by this paper
• Potential net clinical benefit of population-wide implementation of apixaban and dabigatran among European patients with atrial fibrillation

  2012cited by this paper
• Regional variations in cardiovascular risk factors in India: India heart watch.

  2012cited by this paper
• Rationale and design of a Global Rheumatic Heart Disease Registry: the REMEDY study.

  2012cited by this paper
• UK research expenditure on dementia, heart disease, stroke and cancer: are levels of spending related to disease burden?

  2012cited by this paper
• Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey.

  2011cited by this paper
• IMPACT: A Generic Tool for Modelling and Simulating Public Health Policy

  2011cited by this paper
• Legal challenge to India’s patent laws threatens access to generic drugs, says charity

  2011cited by this paper
• Apixaban versus warfarin in patients with atrial fibrillation.

  2011cited by this paper
• Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.

  2011cited by this paper
• Global cardiovascular health: urgent need for an intersectoral approach.

  2011cited by this paper
• Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a ‘real world’ atrial fibrillation population: A modelling analysis based on a nationwide cohort study

  2011cited by this paper
• National spending on cardiovascular disease, 1996-2008.

  2011cited by this paper
• The value of atorvastatin over the product life cycle in the United States.

  2011cited by this paper
• A Cross-Sectional Study of the Microeconomic Impact of Cardiovascular Disease Hospitalization in Four Low- and Middle-Income Countries

  2011cited by this paper
• How many "me-too" drugs is too many?

  2011cited by this paper
• A New Landscape for Stroke Prevention in Atrial Fibrillation: Focus on New Anticoagulants, Antiarrhythmic Drugs, and Devices

  2011cited by this paper
• UN High-Level Meeting on Non-Communicable Diseases: addressing four questions.

  2011cited by this paper
• Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a ‘real world’ nationwide cohort study

  2011cited by this paper
• Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.

  2011cited by this paper
• Novel anticoagulants for stroke prevention in atrial fibrillation: current clinical evidence and future developments.

  2010cited by this paper
• Algorithms for enhancing public health utility of national causes-of-death data

  2010cited by this paper
• Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation.

  2010cited by this paper
• Availability, price and affordability of cardiovascular medicines: A comparison across 36 countries using WHO/HAI data

  2010cited by this paper
• The Health Impact Fund: incentives for improving access to medicines.

  2010cited by this paper
• The Vioxx pharmaceutical scandal: Peterson v Merke Sharpe & Dohme (Aust) Pty Ltd (2010) 184 FCR 1.

  2010cited by this paper
• Medical devices: managing the mismatch : an outcome of the priority medical devices project

  2010cited by this paper
• A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey.

  2010cited by this paper
• Medical devices: managing the mismatch : an outcome of the priority medical devices project

  2010cited by this paper
• Lessons from 60 years of pharmaceutical innovation

  2009cited by this paper
• Ethical considerations in cardiovascular prevention

  2009cited by this paper
• Dabigatran versus warfarin in patients with atrial fibrillation.

  2009cited by this paper
• Effect of clopidogrel added to aspirin in patients with atrial fibrillation.

  2009cited by this paper
• The Net Clinical Benefit of Warfarin Anticoagulation in Atrial Fibrillation

  2009cited by this paper
• The global cost of nonoptimal blood pressure

  2009cited by this paper
• Dabigatran versus warfarin in patients with atrial fibrillation.

  2009cited by this paper
• The Health Impact Fund : Pay-for-Performance

  2009cited by this paper
• The limits of cost-effectiveness analysis.

  2009cited by this paper
• The Health Impact Fund: Making new medicines accessible for all.

  2008cited by this paper
• New-onset atrial fibrillation is an independent predictor of in-hospital mortality in hospitalized heart failure patients: results of the EuroHeart Failure Survey.

  2008cited by this paper
• Global burden of cardiovascular disease

  2007cited by this paper
• Grand challenges in chronic non-communicable diseases

  2007cited by this paper
• Prevention of chronic diseases: a call to action.

  2007cited by this paper
• Sensitivity and Uncertainty Analyses for Burden of Disease and Risk Factor Estimates

  2006cited by this paper
• Sensitivity and Uncertainty Analyses for Burden of Disease and Risk Factor Estimates -- Global Burden of Disease and Risk Factors

  2006cited by this paper
• Has the implementation of the TRIPS Agreement in Latin America and the Caribbean produced intellectual property legislation that favours public health?

  2004cited by this paper
• Ensuring access to essential medicines in the developing countries: A framework for action

  2003cited by this paper
• Reducing the global burden of cardiovascular disease: the role of risk factors.

  2002cited by this paper
• Value of novelty?

  2002cited by this paper
• Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation.

  2001cited by this paper
• Regional administrative health registries as a resource in clinical epidemiology

  1997cited by this paper
• Scenarios , Strategies and the Strategy Process

  1997cited by this paper
• Five-hundred life-saving interventions and their cost-effectiveness.

  1995cited by this paper
• A new landscape

  1981cited by this paper
• THE WORLD HEALTH ORGANIZATION

  1954cited by this paper
• American Journal of Epidemiology Original Contribution the Potentially Modifiable Burden of Incident Heart Failure Due to Obesity the Atherosclerosis Risk in Communities Study

  year unknowncited by this paper

• Human rights obligations of drug companies

  2020cites this paper
• Improving access to medicines via the Health Impact Fund in India: a stakeholder analysis

  2018cites this paper
• A Conceptual Structure of Justice - Providing a Tool to Analyse Conceptions of Justice

  2016cites this paper
• Drugs for cardiovascular disease in India: perspectives of pharmaceutical executives and government officials on access and development-a qualitative analysis

  2016cites this paper
• The pharmaceutical industry and human well being : Argentina and TRIPS

  2015cites this paper
• Sustainability and Justice - Conceptual Foundations and Cases in Biodiversity and Fishery Policy

  2014cites this paper
• Translational ethics: an analytical framework of translational movements between theory and practice and a sketch of a comprehensive approach

  2014cites this paper